[1]
American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2013;. 5th ed.
[2]
Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: A STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006; 163: 210-6.
[3]
Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RM. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry 2006; 163: 1561-8.
[4]
Clemente AS, Diniz BS, Nicolato R, et al. Bipolar disorder prevalence: A systematic review and meta-analysis of the literature. Rev Bras Psiquiatr 2015; 37: 155-61.
[5]
Serafini G, Pompili M, Borgwardt S, et al. Brain changes in early-onset bipolar and unipolar depressive disorders: A systematic review in children and adolescents. Eur Child Adolesc Psychiatry 2014; 23: 1023-41.
[6]
Rizzo LB, Costa LG, Mansur RB, et al. The theory of bipolar disorder as an illness of accelerated aging: Implications for clinical care and research. Neurosci Biobehav Rev 2014; 42: 157-69.
[7]
Barbosa IG, Machado-Vieira R, Soares JC, Teixeira AL. The immunology of bipolar disorder. Neuroimmunomodulation 2014; 21: 117-22.
[8]
Barbosa IG, Bauer ME, Machado-Vieira R, Teixeira AL. Cytokines in bipolar disorder: Paving the way for neuroprogression. Neural Plast 2014; 360-481.
[9]
Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804-17.
[10]
Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 2010; 15(4): 384-92.
[11]
Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: A meta-analysis of 30 studies. Biol Psychiatry 2013; 74: 15-25.
[12]
Munkholm K, Braüner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis. J Psychiatr Res 2013; 47: 1119-33.
[13]
Silverman MN, Pearce BD, Biron CA, Miller AH. Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral Immunol 2005; 18: 41-78.
[14]
Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet 2013; 381: 1672-82.
[15]
Soares JC. Recent advances in the treatment of bipolar mania, depression, mixed states, and rapid cycling. Int Clin Psychopharmacol 2000; 15: 183-96.
[16]
Ketter TA, Sarma K, Silva R, Kroger H, Cucchiaro J, Loebel A. Lurasidone in the long-term treatment of patients with bipolar disorder: A 24-week open-label extension study. Depress Anxiety 2016; 33: 424-34.
[17]
Valvassori SS, Resende WR, Dal-Pont G, et al. Lithium ameliorates sleep deprivation-induced mania-like behavior, hypothalamic-pituitary-adrenal (HPA) axis alterations, oxidative stress and elevations of cytokine concentrations in the brain and serum of mice. Bipolar Disord 2017; 19: 246-58.
[18]
Valvassori SS, Tonin PT, Varela RB, et al. Lithium modulates the production of peripheral and cerebral cytokines in an animal model of mania induced by dextroamphetamine. Bipolar Disord 2015; 17: 507-17.
[19]
Arabzadeh S, Ameli N, Zeinoddini A, et al. Celecoxib adjunctive therapy for acute bipolar mania: A randomized, double-blind, placebo-controlled trial. Bipolar Disord 2015; 17: 606-14.
[20]
Husain MI, Strawbridge R, Stokes PR, Young AH. Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis. J Psychopharmacol 2017; 31: 1137-48.
[21]
Mousavi SY, Khezri R, Karkhaneh-Yousefi MA, et al. Randomized double-blind placebo-controlled trial on effectiveness and safety of celecoxib adjunctive therapy in adolescents with acute bipolar mania. J Child Adolesc Psychopharmacol 2017; 27: 494-500.
[22]
Marnett LJ, Rowlinson WS, Goodwin DC, Kalgutkar AS, Lanzo CA. Arachidonic acid oxygenation by COX-1 and COX-2. J Biol Chem 1999; 274: 22903-6.
[23]
Brooks P, Emery P, Evans JF, et al. Interpreting the clinical significance of the diferential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology 1999; 38: 779-88.
[24]
Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: A pattern of nephrotoxicity similar to traditional nosteroidal anti-inflammatory drugs. Am J Med 2001; 111: 64-7.
[25]
Yaksh TL, Dirig DM, Conway CM, Svensson C, Luo ZD, Isakson PC. The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci 2001; 21: 5847-53.
[26]
Cannon GW, Breedveld FC. Efficacy of cyclooxygenase-2 specific inhibitors. Am J Med 2001; 110: 6-12.
[27]
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic review and meta-analysis of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 2009; 339: b2700.
[28]
Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration..
[29]
Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
[30]
Kargar M, Yousefi A, Mojtahedzadeh M, et al. Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: A placebo-controlled, double-blind, randomised study. Swiss Med Wkly 2014; 144: w13880.
[31]
Kargar M, Yoosefi A, Akhondzadeh S, Artonian V, Ashouri A, Ghaeli P. Effect of adjunctive celecoxib on BDNF in manic patients undergoing electroconvulsive therapy: A randomized double blind controlled trial. Pharmacopsychiatry 2015; 48: 268-73.
[32]
Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008; 23: 87-94.
[33]
Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomized controlled trials. BMJ 2011; 343: d4002.
[34]
Brietzke E, Mansur RB, Soczynska JK, Kapczinski F, Bressan RA, McIntyre RS. Towards a multifactorial approach for prediction of bipolar disorder in at risk populations. J Affect Disord 2012; 140: 82-91.
[35]
Barrientos R, Kitt MM, Watkins LR, Maier SF. Neuroinflammation in the normal aging hippocampus. Neuroscience 2015; 19(309): 84-99.
[36]
Lima RR, Costa AMR, Souza RD, Gomesleal W. Inflamation in neurodegenerative disease. Rev Para Med 2007; 21: 29-34.
[37]
Felger JC, Alagbe O, Hu F. Effects of interferon-alpha on rhesus monkeys: A nonhuman primate model of cytokine-induced depression. Biol Psychiatry 2007; 62(11): 1324-33.
[38]
Miller AH, Maletic V, Raison CL. Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65(9): 732-41.
[39]
Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: Impact on neurotransmitters and neurocircuits. Dep Anx 2013; 30: 297-306.
[40]
Zambalde ÉP, Teixeira MM, Favarin DC, et al. The anti-inflammatory and pro-resolution effects of aspirin-triggered RvD1 (AT-RvD1) on peripheral blood mononuclear cells from patients with severe asthma. Int Immunopharmacol 2016; 35: 142-8.
[41]
Goncharova LB, Tarakanov AO. Molecular networks of brain and immunity. Brain Res Rev 2007; 55: 155-66.
[42]
Muller N, Schwarz MJ. Immune system and schizophrenia. Curr Immunol Rev 2010; 6: 213-20.
[43]
Barbosa IG, Huguet RB, Neves FS, Bauer ME, Teixeira AL. Immunology of bipolar disorder. J Bras Psiquiatr 2009; 58: 52-9.
[44]
Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study. J Affect Disord 2012; 141: 308-14.
[45]
Chen CY, Tzeng NS, Chen YC. Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction. Gen Hosp Psychiatry 2010; 32: 647.
[46]
Faridhosseini F, Sadeghi R, Farid L, Pourgholami M. Celecoxib: A new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol 2014; 29: 216-23.
[47]
Borre Y, Lemstra S, Westphal KG, Morgan ME, Olivier B, Oosting RS. Celecoxib delays cognitive decline in an animal model of neurodegeneration. Behav Brain Res 2012; 234: 285-91.
[48]
Casolini P, Catalani A, Zuena AR, Angelucci L. Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res 2002; 68: 337-43.
[49]
Mirjany M, Ho L, Pasinetti GM. Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity. J Pharmacol Exp Ther 2002; 301: 494-500.
[50]
Raison CL, Capuron L, Miller AH. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol 2006; 27: 24-31.
[51]
Ross BM, Brooks RJ, Lee M, et al. Cyclooxygenase inhibitor modulation of dopamine-related behaviours. Eur J Pharmacol 2002; 450: 141-51.
[52]
Hope S, Dieset I, Agartz I, et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res 2011; 45: 1608-16.
[53]
Husain MI, Chaudhry IB, Hamirani MM, et al. Minocycline and celecoxib as adjunctive treatments for bipolar depression: A study protocol for a multicenter factorial design randomized controlled trial. Neuropsychiatr Dis Treat 2016; 13: 1-8.
[54]
Subramaniam M, Abdin E, Vaingankar JA, et al. Impact of psychiatric disorders and chronic physical conditions on health-related quality of life: Singapore mental health study. J Affect Disord 2013; 147(1-3): 325-30.
[55]
Ferrari AJ, Norman RE, Freedman G, et al. The burden attributable to mental and substance use disorders as risk factors for suicide: Findings from the Global Burden of Disease Study 2010. PLoS One 2014; 29(4): e91936.
82
9
2